Julianna LeMieux and Uduak Thomas discuss their time at the ASHG meeting in Boston and some of the news from the meeting.
AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback